Short‐course blood transfusion therapy with hydroxyurea, a functional strategy in the management of stroke in children with sickle cell disease
Rattachement africain : Nigéria, gb. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Cerebrovascular accidents are serious complications of sickle cell disease (SCD). Children with abnormal transcranial Doppler (TCD) readings are at higher risk for stroke, and those with prior strokes have increased risk of recurrence. Chronic blood transfusion therapy (BTT) is the standard treatment for stroke prevention; hydroxyurea (hydroxycarbamide [HU]), a recommended alternative, is less effective. This study explores the use of modified short BTT combined with HU for stroke prevention in SCD. We reviewed medical records of 170 children (ages 2-16) with abnormal TCD or prior stroke treated with monthly BTT for 6-8 months and HU. TCD results and stroke incidence were assessed 1 year after discontinuing BTT. Among the children, 136 (80%) had abnormal TCD, 15 (11.2%) had current stroke and 19 (8.8%) had prior stroke. After discontinuation of BTT, abnormal TCD readings decreased significantly to 18.7% and 16.9% (p < 0.05); those with normal TCD increased significantly from 38.8% to 52.8% (p < 0.05) after 1 year. TCD velocity decreased significantly during the same period (p < 0.05). Only 2 (1.5%) children with abnormal TCD experienced stroke. Overall, 13 (7.8%) had stroke by 1-year post BTT. In conclusion, the combination of short-course BTT and HU significantly reduced stroke risk and incidence of stroke in children with SCD.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Short‐course blood transfusion therapy with hydroxyurea, a functional strategy in the management of stroke in children with sickle cell disease
- Date Crossref
- 05/04/2026
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Lagos State University Lagos State University, Nigéria (code pays fourni par la source)Université ou école supérieure
-
University of Lagos University of Lagos, Nigéria (code pays fourni par la source)Université ou école supérieure
-
North Hertfordshire College pays non établi dans la noticeUniversité ou école supérieure
-
East and North Hertfordshire NHS Trust pays non établi dans la noticeÉtablissement de santé
-
Lagos University Teaching Hospital Lagos University Teaching Hospital, Nigéria (code pays fourni par la source)Établissement de santé
-
Lagos State University Teaching Hospital Lagos State University Teaching Hospital, Nigéria (code pays fourni par la source)Établissement de santé
-
Nigerian Institute of Medical Research Lagos, Nigéria (code pays fourni par la source)Établissement de santé
-
Department of Paediatrics College of Medicine Lagos, Nigéria (pays nommé en fin d’affiliation)Université ou école supérieure
-
East and North HertfordshireTrust East of England Deanery Stevenage UK pays non établi dans la noticeInstitution
-
Blood Transfusion College of Medicine Department of Haematology & Lagos, Nigéria (pays nommé en fin d’affiliation)Université ou école supérieure
Lagos State University (Lagos State University, Nigéria), University of Lagos (University of Lagos, Nigéria) et North Hertfordshire College, avec 7 autres affiliations. Pays d’affiliation : Nigéria.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.